Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05271318 · ClinicalTrials.gov registry record · Phase 1

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

A Phase 1 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma, sponsored by TILT Biotherapeutics.

Recruiting
Registry status
Phase 1
Development phase
29
Enrollment target
3
Study locations

NCT05271318: Recruiting Phase 1 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma, sponsored by TILT Biotherapeutics.

NCT05271318 is a Phase 1 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma that is actively recruiting participants, run by TILT Biotherapeutics. The registered enrollment target is 29 participants, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05271318, a Phase 1 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma, is actively recruiting participants, sponsored by TILT Biotherapeutics.

RECRUITING
Registry status
Phase 1
Development phase
29 participants
Enrollment target
3
Study locations

Study Summary

This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.

Conditions Studied

Platinum-resistant Ovarian Cancer Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Platinum-refractory Ovarian Carcinoma Platinum-Refractory Fallopian Tube Carcinoma Platinum-Refractory Primary Peritoneal Carcinoma Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin

Interventions

  • BIOLOGICAL TILT-123
  • BIOLOGICAL pembrolizumab
  • DRUG pegylated liposomal doxorubicin

Study Locations (3)

Minnesota

  • Mayo Clinic - Rochester

New York

  • Northwell Heatlh/Lenox Hill Hospital - New York

Other

  • Docrates Cancer Center - Helsinki

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2022-05-17
Est. Completion 2027-08
Phase Phase 1
TILT Biotherapeutics

3 total trials

What NCT05271318 shows while recruiting

NCT05271318 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (84% lower).

The record links to 9 conditions, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which TILT-123 is the first listed.

NCT05271318 reports a single indexed study location in Minnesota, New York, Other.

Frequently Asked Questions

What is clinical trial NCT05271318 about?

NCT05271318 is a clinical study titled "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.". This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.

What is the current status of trial NCT05271318?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-05-17. Estimated completion is 2027-08.

What conditions does trial NCT05271318 study?

This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-refractory Ovarian Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma.

What interventions are being tested in trial NCT05271318?

The interventions under investigation include: TILT-123 (BIOLOGICAL), pembrolizumab (BIOLOGICAL), pegylated liposomal doxorubicin (DRUG).

Who is sponsoring clinical trial NCT05271318?

This trial is sponsored by TILT Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05271318 being conducted?

This trial has 3 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Platinum-resistant Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05271318's enrollment target sits among peer trials

29 16th of 17 higher than 2 of 17 other Platinum-resistant Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Platinum-resistant Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05271318

Source: ClinicalTrials.gov NCT05271318, the US trial registry maintained by the National Library of Medicine. NCT05271318 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.